Insulin use without oral medications for glycemic management was associated with a higher risk of prostate cancer mortality (HR, 1.23; 95% CI, 1.05–1.45), whereas oral medication prescriptions and combinations of insulin and oral glucose-lowering agents were not associated with significant differences in mortality, compared with patients without antihyperglycemic medications. This evidence concerns the gene INS and prostate carcinoma.